Johnson & Johnson (JNJ)vsSeres Therapeutics Inc (MCRB)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
MCRB
Seres Therapeutics Inc
$7.05
-0.56%
HEALTHCARE · Cap: $67.91M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 12213081% more annual revenue ($96.36B vs $789,000). MCRB leads profitability with a 722.0% profit margin vs 21.8%. MCRB trades at a lower P/E of 11.0x. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
MCRB
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Intrinsic value data unavailable for MCRB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Attractively priced relative to earnings
Keeps 722 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
Elevated debt levels
Revenue declined 93.4%
Earnings declined 91.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : MCRB
The strongest argument for MCRB centers on P/E Ratio, Profit Margin, Price/Book. Profitability is solid with margins at 722.0% and operating margin at -4424.0%.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : MCRB
The primary concerns for MCRB are Market Cap, Debt/Equity, Revenue Growth. Debt-to-equity of 1.95 is elevated, increasing financial risk.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MCRB is a declining play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.33 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 35/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Seres Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?